Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Lung CancerCondition:Lung CancerMolecule:Tislelizumab
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCondition:Gastric Cancer, Esophageal CancerMolecule:Tislelizumab
- A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCondition:LymphomaMolecule:Tislelizumab
- BGB-A317-002 [No Study Record]Condition:Advanced solid tumorsMolecule:Tislelizumab
- Study of the Safety, Pharmacokinetics and Antitumor Activities of Tislelizumab in Subjects With Advanced TumorsCondition:Advanced solid tumorsMolecule:Tislelizumab
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent GlioblastomaCondition:GlioblastomaMolecule:Pamiparib + Radiotherapy and/or Temozolomide [1L] and Pamiparib + Temozolomide [R/R])
- Study to Assess Safety, Tolerability and Clinical Activity of Pamiparib in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid TumorsCondition:Advanced solid tumorsMolecule:Pamiparib + Temozolomide
- The Safety, Pharmacokinetics and Antitumor Activity of Tislelizumab in Combination With Pamiparib in Subjects With Advanced Solid TumorsCondition:Advanced solid tumorsMolecule:Tislelizumab + Pamiparib
- Study of Pamiparib or Placebo in Patients With Advanced or Inoperable Gastric CancerCondition:Gastric CancerMolecule:Pamiparib
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Pamiparib Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian CancerCondition:Ovarian CancerMolecule:Pamiparib
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.